secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001867096-24-000102
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris stockholders approve all proposals; ESPP shares increased by 6.64M
------------------------------------------------------------------------

- Third director nominees elected: Edick, Fairley, Persky (58.5M, 58.5M, 47.4M for).
- Ernst & Young ratified as auditor for FY2024 (99.5M for).
- Advisory vote on executive compensation approved (57.8M for); frequency set at 1 year.
- ESPP amendment approved: evergreen provision removed; shares increased by 6,636,632 to 8,854,709.
- Broker non-votes on director election and advisory items: ~36.2M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000102/0001867096-24-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000102/xers-20240605.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer